Singapore-based Esco Lifesciences, which provides products and services for the life sciences and healthcare industries, has announced the closure of an oversubscribed $200 million Series A and crossover round led by Vivo Capital and Novo Holdings.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
